Pharmacovigilance teams need to show that safety activities are controlled, documented, and working as intended. This article explains what quality and compliance monitoring means in pharmacovigilance, which processes need oversight, and how organisations can use evidence, review, and corrective action to remain inspection-ready without treating monitoring as a last-minute exercise.
Quality and compliance monitoring provide a way to maintain accurate, consistent and compliant pharmacovigilance activities. Rather than functioning as isolated quality assurance activities, they should be embedded throughout the pharmacovigilance lifecycle to ensure safety information is managed effectively, regulatory obligations are fulfilled and opportunities for improvement are identified early.
In Brief
- Quality and compliance monitoring assesses both how well pharmacovigilance processes are working and whether regulatory and organisational requirements are being followed.
- Effective monitoring supports patient safety by identifying issues in safety data, reporting timelines, process performance, and regulatory compliance.
- In practice, monitoring spans governance, training, documentation, outsourced activities, key PV processes, KPIs, audits, deviations, and CAPA.
- Routine metrics alone may not reveal issues such as unclear data movement, weak access controls, or missing evidence of how safety decisions were made.
- A proportionate, risk-based approach helps teams focus oversight where failures could have the greatest safety, compliance, or operational impact.
What is Quality and Compliance Monitoring?
Quality monitoring evaluates whether pharmacovigilance processes are effective, consistent and improving over time through quality reviews, Key Performance Indicator (KPI) monitoring, deviation management and Corrective and Preventive Actions (CAPAs). Compliance monitoring evaluates adherence to applicable regulations, internal procedures and contractual obligations. Together, they support patient safety, process control, and inspection readiness. This matters because effective monitoring protects patients by ensuring safety data are complete, accurate and reported within required timelines.
Building a Pharmacovigilance Quality Management System
An effective pharmacovigilance (PV) Quality Management System (QMS) provides framework for ensuring that pharmacovigilance activities are planned, performed, monitored and improved throughout the product lifecycle. Beyond supporting regulatory compliance, a mature PV QMS promotes consistent decision-making, strengthens governance, protects data integrity and enables organisations to identify and mitigate quality risks.
Monitoring effort should be proportionate to the risk of the process being monitored. Organisations should prioritise activities based on process criticality, potential safety impact, regulatory obligation, previous findings and known weaknesses, rather than applying the same level of review to every activity.
Core Components of a PV QMS
- Governance and leadership commitment
- Quality objectives and quality culture
- Documented policies, SOPs, and work instructions
- Role-based training and compliance oversight
- Deviation management and root cause analysis
- Corrective and Preventive Actions (CAPA)
- Management review and continuous improvement
Governance and Oversight
Senior management should establish clear governance structures, allocate appropriate resources and promote a culture where quality is embedded into daily pharmacovigilance activities. Governance should include regular quality review meetings, escalation pathways, vendor oversight and management review of quality metrics. Where relevant, oversight should also make clear how the Qualified Person Responsible for Pharmacovigilance (QPPV), sponsor, MAH or delegated safety lead maintains visibility of key risks, outsourced activities and unresolved compliance issues.
For delegated PV activities, sponsors and marketing authorisation holders remain accountable for appropriate pharmacovigilance oversight and should be able to demonstrate that this responsibility has not simply been transferred to a CRO or vendor. This includes documenting clear responsibilities, maintaining visibility of delegated activities, monitoring compliance and performance, reviewing emerging issues, and ensuring that appropriate escalation and corrective action take place when needed. Regular compliance reporting can support documented evidence of this ongoing oversight.
Documentation and Record Management
Controlled documentation is fundamental to a compliant PV system. Organisations should maintain approved SOPs, version-controlled documentation, audit trails, validated electronic systems and document retention processes that support traceability and inspection readiness. Procedures should also be reviewed, approved, distributed, available to relevant personnel, and supported by training before they become effective. Records should also be retained in a way that supports timely access, confidentiality, appropriate access controls, and data integrity. Inspection readiness should be maintained continuously rather than initiated immediately before an inspection. Organisations should ensure documentation is current, training records are complete, audit trails are available and quality metrics are regularly reviewed by management.
Where applicable, the pharmacovigilance system master file (PSMF) should reflect current PV operations and support inspection-ready evidence of responsibilities, processes, systems, and outsourced activities. Technology should be discussed through the controls that affect quality and compliance monitoring, such as validated systems, controlled records, audit trails, access controls, data integrity, and clear oversight of automated workflows.
Training and Competency
Training should extend beyond completion records. Organisations should evaluate competency through role-specific training, periodic refreshers, quality review outcomes and effectiveness assessments to ensure personnel remain qualified for their assigned responsibilities.
Example Quality Metrics
| Quality Metric | Purpose |
| Individual Case Safety Report (ICSR) reporting timeliness | Measure regulatory compliance |
| QC error rate | Assess process quality |
| CAPA effectiveness | Confirm sustainable improvement |
| Literature monitoring compliance | Evaluate surveillance performance |
| Vendor performance | Support outsourced PV oversight |
For example, a sponsor outsourcing pharmacovigilance activity to a service provider may retain overall oversight through governance meetings, compliance reports, KPI dashboards, periodic vendor audits and management reviews. This approach ensures consistent quality standards and timely identification of emerging compliance risks.
Monitoring Quality and Compliance in Practice
A pharmacovigilance quality management system depends on routine monitoring activities that evaluate process performance, identify emerging risks and demonstrate regulatory compliance. Monitoring should be proactive, risk-based and based on data, enabling organisations to detect trends early and implement timely corrective actions.
Which Pharmacovigilance Processes Should Be Monitored?
- Case intake and ICSR processing
- Medical review and narrative quality
- MedDRA and WHODrug coding accuracy
- Literature surveillance
- Signal detection and signal management
- Aggregate reporting
- Risk Management Plan commitments
- Regulatory submissions and reporting timelines
- Safety communications and authority commitments
- Vendor oversight and service level compliance
Key Performance Indicators (KPIs) and Key Risk Indicators (KPIs)
Meaningful KPIs and KRIs enable organisations to evaluate both operational performance and regulatory compliance. Metrics should be reviewed periodically to identify trends rather than isolated events.
| Metric | Purpose | Example |
| ICSR submission timeliness | Monitor regulatory compliance | % expedited cases submitted on time |
| QC Error Rate | Assess quality | Critical findings per review cycle |
| Periodic report submission timeliness | Monitor regulatory compliance | % periodic reports submitted on time |
| Vendor KPI | Oversight | SLA adherence |
| CAPA Effectiveness | Continuous improvement | Repeat deviation rate |
Common warning signs include late reporting, case backlogs, repeated quality-control errors, weak documentation, missing audit trails, outdated SOPs, training gaps and unresolved vendor performance issues. Some risks are less visible in routine metrics, such as unclear data movement between systems, weak access control, missing decision rationales, or records that cannot show how a safety issue was assessed. These signs do not automatically mean a system has failed, but they should prompt review before issues become harder to correct.
Deviation Management and CAPA
Quality monitoring should identify deviations promptly, determine the underlying root cause and implement effective CAPAs. Effectiveness checks should confirm that actions have resolved the issue and prevented recurrence rather than simply documenting closure. In practice, regulatory inspectors frequently expect evidence that CAPAs addressed the underlying root cause and that their effectiveness was verified through ongoing quality monitoring.
Continuous Improvement
Continuous improvement is a core principle of an effective PV Quality Management System. Organisations should evaluate quality metrics, audit findings, deviations, CAPA effectiveness and management reviews to identify recurring trends and implement sustainable improvements using a Plan–Do–Check–Act approach. Audits should be planned with the risk profile in mind, including product complexity, previous findings, inspection history, outsourced activities, and changes to systems or processes.
PV quality systems and procedures should also be reviewed when regulatory requirements change, new safety signals emerge, audit findings identify weaknesses, compliance incidents occur, product volumes change, outsourced activities change, systems are updated or organisational responsibilities shift. Regular review remains important alongside triggered review, because some weaknesses only become visible through trend analysis over time.
Conclusion
Quality and compliance monitoring are fundamental to maintaining an effective pharmacovigilance system. By embedding quality into governance, documentation, training, operational oversight and continuous improvement, organisations can strengthen patient safety, support benefit–risk decision-making and remain inspection ready throughout the product lifecycle. The practical value lies in clear ownership, accessible evidence, routine review and proven corrective action.
About QVigilance
We are a specialised pharmacovigilance service provider, offering comprehensive pharmacovigilance services to sponsors of clinical trials and manufacturers of authorised medicinal products. QVigilance is adept in supporting customers establishing a compliant pharmacovigilance system to support our customers’ products and safeguard their patients.
FAQs
What is the difference between quality and compliance monitoring?
Quality monitoring evaluates process effectiveness, while compliance monitoring evaluates adherence to regulatory requirements and procedures.
Why are CAPAs important?
CAPAs address root causes of quality issues and prevent recurrence.
How often should quality systems be reviewed?
Regular routine reviews should be supplemented by reviews following major regulatory, organisational, or system changes.